T
Tanaji Dasgupta
Researcher at Clinical Trial Service Unit
Publications - 6
Citations - 2331
Tanaji Dasgupta is an academic researcher from Clinical Trial Service Unit. The author has contributed to research in topics: Kidney disease & Mortality rate. The author has an hindex of 4, co-authored 4 publications receiving 2099 citations.
Papers
More filters
Journal ArticleDOI
The effects of lowering LDL cholesterol with simvastatin plus ezetimibe in patients with chronic kidney disease (Study of Heart and Renal Protection): a randomised placebo-controlled trial
Colin Baigent,Martin J Landray,Christina Reith,Jonathan Emberson,David C. Wheeler,Charles R.V. Tomson,Christoph Wanner,Vera Krane,Alan Cass,Jonathan C. Craig,Bruce Neal,Lixin Jiang,Lai Seong Hooi,Adeera Levin,Lawrence Y. Agodoa,Mike Gaziano,Bertram L. Kasiske,Robert J. Walker,Ziad A. Massy,Bo Feldt-Rasmussen,Udom Krairittichai,Vuddidhej Ophascharoensuk,Bengt Fellström,Hallvard Holdaas,Vladimir Tesar,Andrzej Wiecek,Diederick E. Grobbee,Dick de Zeeuw,Carola Grönhagen-Riska,Tanaji Dasgupta,David Lewis,William G. Herrington,Marion Mafham,William Majoni,K Wallendszus,Richard H. Grimm,Terje R. Pedersen,Jonathan A. Tobert,Jane Armitage,Alex Baxter,Christopher Bray,Yiping Chen,Zhengming Chen,Michael Hill,Carol Knott,Sarah Parish,David Simpson,Peter Sleight,Alan Young,Rory Collins +49 more
TL;DR: Reduction of LDL cholesterol with simvastatin 20 mg plus ezetimibe 10 mg daily safely reduced the incidence of major atherosclerotic events in a wide range of patients with advanced chronic kidney disease.
Journal ArticleDOI
Prediction of ESRD and Death Among People With CKD: The Chronic Renal Impairment in Birmingham (CRIB) Prospective Cohort Study
Martin J Landray,Jonathan Emberson,Lisa Blackwell,Tanaji Dasgupta,Rosita Zakeri,Matthew D. Morgan,Charles J. Ferro,Susan Vickery,Puja Ayrton,Devaki Nair,R. Neil Dalton,Edmund J. Lamb,Colin Baigent,Jonathan N. Townend,David C. Wheeler +14 more
TL;DR: Simple laboratory measures of kidney and cardiac function plus age, sex, and smoking history can be used to help identify patients with CKD at highest risk of ESRD and death.
Journal ArticleDOI
Serum free light chains and the risk of ESRD and death in CKD.
Richard Haynes,Colin A. Hutchison,Jonathan Emberson,Tanaji Dasgupta,David C. Wheeler,John N. Townend,Martin J Landray,Paul Cockwell +7 more
TL;DR: Associations between monoclonal and polyclonal excess of sFLCs and risk of ESRD are explained by the correlation between these measures and renal function.
Journal ArticleDOI
Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men
Jonathan Emberson,Richard Haynes,Tanaji Dasgupta,Marion Mafham,Martin J Landray,Colin Baigent,Robert Clarke +6 more
TL;DR: Cystatin C and risk of vascular and nonvascular mortality: a prospective cohort study of older men and J Intern Med 2010; 268: 145–154.
Journal ArticleDOI
Concurrent development of encapsulating peritoneal sclerosis and calciphylaxis in a patient with peritoneal dialysis for end-stage renal disease
TL;DR: A unique case of a 73-year-old female patient who had undergone 8 years of peritoneal dialysis for IgA nephropathy and concurrently developed these two synchronous complications within 3 months of each other is discussed.